Smoothing the Bumpy Road to Antiarrhythmic Drug Development.
From the Manchester Royal Infirmary, Manchester, United Kingdom (V.M.R.); Lankenau Institute for Medical Research, Philadelphia, PA (V.M.R., P.R.K.); and Jefferson Medical College, Philadelphia, PA (P.R.K.).
Victoria M
VM
Robinson
From the Manchester Royal Infirmary, Manchester, United Kingdom (V.M.R.); Lankenau Institute for Medical Research, Philadelphia, PA (V.M.R., P.R.K.); and Jefferson Medical College, Philadelphia, PA (P.R.K.). koweyp@mlhs.org.
Peter R
PR
Kowey
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy*; D026902:Potassium Channel Blockers / Q000627:therapeutic use*; D026941:Sodium Channel Blockers / Q000627:therapeutic use*
D000889:Anti-Arrhythmia Agents; D026902:Potassium Channel Blockers; D026941:Sodium Channel Blockers
Editorials; anti-arrhythmia agents; atrial fibrillation; computers; ion channels